TY - T1的哮喘和冠状病毒病2019风险:系统回顾和荟萃分析JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01209 -2021欧元SP - 2101209 AU -安东尼·p·Sunjaya盟Sabine m . Allida盟——吉安卢卡·迪坦拿非盟-克里斯汀·r·詹金斯Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/08/19/13993003.01209 - 2021. -抽象N2 -背景个案系列和群组研究报道相互矛盾的结果的脆弱性和风险从COVID-19哮喘患者的死亡率。研究问题是哮喘患者在被感染的风险更高,住院或贫穷从COVID-19临床结果吗?方法基于五个主要数据库的系统回顾和荟萃分析包括COVID-19数据库在12月1日2019年7月11日,2021年在研究控制(non-asthma)组。患病率和风险比率混合使用Sidik-Jonkman随机影响的荟萃分析。发现51个研究用8.08% (95% CI 6.87 - -9.30)汇集的患有哮喘患病率COVID-19阳性病例。风险比为0.83 (95% CI 0.73 - -0.95, p = 0.01)获取COVID-19;1.18 (95% CI 0.98 - -1.42, p = 0.08),住院治疗;1.21 (95% CI 0.97 - -1.51, p = 0.09)入住ICU;1.06 (95% CI 0.82 - -1.36, p = 0.65)用于通风机0.94 (95% CI 0.76 - -1.17;p = 0.58)为哮喘患者死亡率。子群分析由大陆透露收购COVID-19风险显著差异,入住ICU、应用呼吸机和死亡之间的大洲。解释被感染的风险SARS-CoV-2 non-asthma组相比降低了。 No statistically significant differences in hospitalisation, ICU admission and ventilator use were found between groups. Subgroup analyses showed significant differences in outcomes from COVID-19 between America, Europe and Asia. Additional studies are required to confirm this risk profile, particularly in Africa and South America where few studies originate.The risk of being infected with SARS-CoV-2 was reduced compared to the non-asthma group. No significant differences in hospitalisation, ICU admission, ventilator use and mortali were found between groups. ER -